Literature DB >> 7535224

Catecholaminergic function and P300 amplitude in major depressive disorder (P300 and catecholamines).

M Hansenne1, W Pitchot, A Gonzalez Moreno, P Papart, M Timsit-Berthier, M Ansseau.   

Abstract

The neurobiology of P300 is still a subject of controversy. P300 amplitude appears to be modulated by multiple neurotransmitter systems, especially dopaminergic, noradrenergic as well as cholinergic and GABAergic. In this study, we investigated the relationship between P300 amplitude and catecholaminergic neurotransmission as assessed by the growth hormone (GH) response to clonidine and apomorphine challenges in 20 major depressive patients. Results showed a correlation of P300 amplitude with the apomorphine test (r = 0.54; P = 0.01), but not with the clonidine test (r = 0.22; NS). This study supports a role for dopamine in the neurobiological modulation of P300 amplitude.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535224     DOI: 10.1016/0168-5597(94)00317-8

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  4 in total

Review 1.  Updating P300: an integrative theory of P3a and P3b.

Authors:  John Polich
Journal:  Clin Neurophysiol       Date:  2007-06-18       Impact factor: 3.708

2.  Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study.

Authors:  HeeSeung Lee; Grace Y Wang; Louise E Curley; John J Sollers; Rob R Kydd; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2015-12-03       Impact factor: 4.530

3.  Cognitive processing of orientation discrimination in anisometropic amblyopia.

Authors:  Jianglan Wang; Jiao Zhao; Shoujing Wang; Rui Gong; Zhong Zheng; Longqian Liu
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

Review 4.  Neurophysiology in psychosis: The quest for disease biomarkers.

Authors:  Baihan Wang; Eirini Zartaloudi; Jennifer F Linden; Elvira Bramon
Journal:  Transl Psychiatry       Date:  2022-03-11       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.